Posted inMarket
BTIG Raises Climb Bio Stock Price Target to $32 Following Phase 1 Data
BTIG has increased its price target for Climb Bio stock to $32 following promising phase 1 clinical trial data results.
Posted inMarket
Baird Increases Climb Bio Stock Price Target Following Trial Data
Financial firm Baird has raised its price target for Climb Bio stock to $25 following recent clinical trial data updates.
